替雷利珠单抗联合贝伐珠单抗对晚期非小细胞肺癌化疗患者的疗效  

Efficacy of Tirellizumab combined with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer Treated with Chemotherapy

作　　者：施向荣[1] SHI Xiang-Rong(Department of Medical Oncology,Nantong Cancer Hospital,Nantong 226001,China)

机构地区：[1]南通市肿瘤医院肿瘤内科,江苏南通226001

出　　处：《中国药物经济学》2025年第3期55-59,共5页China Journal of Pharmaceutical Economics

摘　　要：目的探讨替雷利珠单抗联合贝伐珠单抗对晚期非小细胞肺癌(NSCLC)化疗患者的疗效。方法选取2020年7月至2022年7月南通市肿瘤医院收治的29例采用一线替雷利珠单抗联合贝伐珠单抗^(+)化疗治疗的晚期NSCLC患者作为观察组,另选同期30例采取一线贝伐珠单抗+化疗治疗的晚期NSCLC患者为对照组。比较两组患者临床疗效,无进展生存期(PFS),治疗前后免疫功能指标及相关肿瘤标志物水平变化,不良反应发生情况。结果观察组客观缓解率、疾病控制率均高于对照组(P<0.05);对照组中位PFS为(5.40±1.32)个月,观察组中位PFS为(6.66±2.13)个月,观察组长于对照组(t=2.741,P=0.008);治疗后两组CD4^(+)/CD8^(+)、CD3^(+)、CD4^(+)均降低(P<0.05),但观察组CD4^(+)/CD8^(+)、CD3^(+)、CD4^(+)均高于对照组(P<0.05);治疗后,两组血清人细胞角蛋白21-1片段(Cyfra21-1)、糖类抗原125(CA125)、癌胚抗原(CEA)水平均降低(P<0.05),且观察组血清Cyfra21-1、CA125、CEA水平均低于对照组(P<0.05);两组骨髓抑制、胃肠道反应、血小板减少、肝肾损伤、白细胞减少发生率比较差异无统计学意义(P>0.05)。结论替雷利珠单抗联合贝伐珠单抗治疗晚期NSCLC化疗患者疗效显著,可延长生存期,改善免疫功能,降低相关肿瘤标志物水平,且安全性较高。Objective To explore the therapeutic effect of combination therapy with tirolizumab and bevacizumab on chemotherapy patients with advanced non-small cell lung cancer.Methods Twenty-nine patients with advanced NSCLC treated with Tirelizumab combined with bevacizumab from July 2020 to July 2022 in Nantong Cancer Hospital were selected as the observation group,and 30patients with advanced NSCLC treated with bevacizumab during the same period were selected as the control group.Clinical efficacy,progression-free survival(PFS),changes in immune function indexes and related tumor markers before and after treatment,and occurrence of adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate of observation group were higher than those of control group(P<0.05).The median PFS of the control group was(5.40±1.32)months,and the median PFS of the observation group was(6.66±2.13)months,The group length of the observation group was longer than the control group(t=2.741,P=0.008).After treatment,CD4^(+)/CD8^(+),CD3^(+)and CD4^(+)were decreased in both groups(P<0.05),but CD4^(+)/CD8^(+),CD3^(+)and CD4^(+)in observation group were higher than those in control group(P<0.05).After treatment,serum levels of human cell keratin 21-1 fragment(Cyfra21-1),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)in 2 groups were decreased(P<0.05),and serum levels of Cyfra21-1,CA125 and CEA in observation group were lower than those in control group(P<0.05).There was no significant difference in the incidence of bone marrow suppression,gastrointestinal reaction,thrombocytopenia,liver and kidney injury and leukopenia between the two groups(P>0.05).Conclusion Tirellizumab combined with bevacizumab is effective in the treatment of advanced non-small cell lung cancer patients with chemotherapy,which can prolong survival,improve immune function,reduce the level of related tumor markers,and has high safety.

关 键 词：替雷利珠单抗 贝伐珠单抗 非小细胞肺癌 晚期 无进展生存期 不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]